Drug Search Results
More Filters [+]

Daglutril

Alternative Names: daglutril
Latest Update: 2009-01-30
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Neprilysin Inhibitor,EP Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Solvay Pharm
Company Location: 1120 BRUSSELS C9 00000
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Daglutril

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hypertension|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

S306.2.008

P2

Completed

Hypertension

None

S306.2.009

P2

Completed

Hypertension|Kidney Diseases

None

Recent News Events

Date

Type

Title